Nuvectis Pharma to Present at H.C. Wainwright BioConnect Conference

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, has announced that its Chairman and Chief Executive Officer, Ron Bentsur, will be presenting at the H.C. Wainwright 2nd BioConnect Investor Conference. This event is scheduled to take place at the NASDAQ world headquarters in New York City on May 20th, 2024, at 12:00 PM Eastern Time.

Nuvectis Pharma is dedicated to the development of innovative precision medicines aimed at addressing serious oncological conditions that lack effective treatment options. The company is advancing two primary clinical-stage drug candidates, NXP800 and NXP900.

NXP800 is an oral small molecule GCN2 activator. It is currently undergoing a Phase 1b clinical trial targeting platinum-resistant, ARID1a-mutated ovarian carcinoma. Additionally, NXP800 is being tested in an Investigator-sponsored clinical trial for cholangiocarcinoma. The U.S. Food and Drug Administration (FDA) has recognized the promise of NXP800 by granting it Fast Track Designation for treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma and Orphan Drug Designation for cholangiocarcinoma.

The second drug candidate, NXP900, is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), which includes SRC and YES1. NXP900 stands out due to its unique mechanism of action, which inhibits both the catalytic and scaffolding functions of the SRC kinase. This dual inhibition results in a comprehensive shutdown of the SRC signaling pathway. Presently, NXP900 is in a Phase 1a dose escalation study.

Nuvectis Pharma's ongoing research and development efforts underscore its commitment to addressing unmet medical needs in oncology with precision medicines. The company's participation in the H.C. Wainwright 2nd BioConnect Investor Conference is anticipated to provide valuable insights into its progress and future directions.

By focusing on these innovative drug candidates, Nuvectis aims to make significant strides in the treatment of challenging oncological conditions, potentially improving outcomes for patients who currently have limited options.